These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32210906)

  • 1. The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
    Abdullah L; Crawford F; Tsolaki M; Börjesson-Hanson A; Olde Rikkert M; Pasquier F; Wallin A; Kennelly S; Ait-Ghezala G; Paris D; Hendrix S; Blennow K; Lawlor B; Mullan M
    Front Neurol; 2020; 11():149. PubMed ID: 32210906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
    Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
    PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.
    Lawlor B; Kennelly S; O'Dwyer S; Cregg F; Walsh C; Coen R; Kenny RA; Howard R; Murphy C; Adams J; Daly L; Segurado R; Gaynor S; Crawford F; Mullan M; Lucca U; Banzi R; Pasquier F; Breuilh L; Riepe M; Kalman J; Wallin A; Borjesson A; Molloy W; Tsolaki M; Olde Rikkert M
    BMJ Open; 2014 Oct; 4(10):e006364. PubMed ID: 25300460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.
    Janelidze S; Hertze J; Zetterberg H; Landqvist Waldö M; Santillo A; Blennow K; Hansson O
    Ann Clin Transl Neurol; 2016 Jan; 3(1):12-20. PubMed ID: 26783546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
    Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
    Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow.
    Meulenbroek O; O'Dwyer S; de Jong D; van Spijker G; Kennelly S; Cregg F; Olde Rikkert M; Abdullah L; Wallin A; Walsh C; Coen R; Kenny RA; Daly L; Segurado R; Borjesson-Hanson A; Crawford F; Mullan M; Lucca U; Banzi R; Pasquier F; Breuilh L; Riepe M; Kalman J; Molloy W; Tsolaki M; Howard R; Adams J; Gaynor S; Lawlor B
    BMJ Open; 2016 Jul; 6(7):e011584. PubMed ID: 27436668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
    Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
    Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
    Dyer AH; Murphy C; Segurado R; Lawlor B; Kennelly SP;
    J Gerontol A Biol Sci Med Sci; 2020 Apr; 75(5):987-994. PubMed ID: 31613323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD.
    Dyer AH; Lawlor B; Kennelly SP;
    BMC Geriatr; 2020 Mar; 20(1):117. PubMed ID: 32228468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.
    Matthews DC; Kinney JW; Ritter A; Andrews RD; Toledano Strom EN; Lukic AS; Koenig LN; Revta C; Fillit HM; Zhong K; Tousi B; Leverenz JB; Feldman HH; Cummings J
    Alzheimers Dement (N Y); 2024; 10(3):e12490. PubMed ID: 38988416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD.
    Dyer AH; Murphy C; Lawlor B; Kennelly SP;
    J Am Med Dir Assoc; 2020 Feb; 21(2):194-200. PubMed ID: 31604674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease.
    Gold M
    J Clin Psychiatry; 2007 Mar; 68(3):430-8. PubMed ID: 17388715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.